Aflibercept Ophthalmic

DRUG4 trials

Sponsors

University of California, Los Angeles, Wake Forest University Health Sciences, Siriraj Hospital, Innovent Biologics (Suzhou) Co. Ltd.

Conditions

Glaucoma Secondary to Eye InflammationIntraocular PressureNeovascular Age-related Macular DegenerationNeovascular GlaucomaRetinal Vein OcclusionVascular Endothelial Growth Factor OverexpressionWet Macular Degeneration

Phase 3

A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD

Active, not recruitingNCT05972473

Innovent Biologics (Suzhou) Co. Ltd.Neovascular Age-related Macular Degeneration

Start: 2023-09-21End: 2027-04-30Updated: 2025-03-13

Phase 4

The IAI-OCTA Study; a Study of OCT-Angiography Analysis Efficacy

CompletedNCT03022292

University of California, Los AngelesWet Macular Degeneration

Start: 2017-03-30End: 2020-08-31Updated: 2022-01-06

Vascular Endothelial Growth Factor (VEGF) Levels in Retinal Vein Occlusion (RVO) During Anti-VEGF Treatment

TerminatedNCT04707625

Wake Forest University Health SciencesRetinal Vein Occlusion

Start: 2021-10-06End: 2023-12-18Updated: 2025-02-24

Unknown Phase

Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma

CompletedNCT04970251

Siriraj HospitalGlaucoma Secondary to Eye Inflammation, Intraocular Pressure, Neovascular Glaucoma +1

Start: 2018-11-01End: 2021-03-31Updated: 2021-07-21